Oncology
Prostate Cancer
Expert Roundtables Podcast Spotlight: Cardiovascular Risk in Advanced Prostate Cancer
Overview
<p>Debate exists, but some evidence suggests GnRH antagonists might have a lower cardiovascular (CV) risk profile than agonists, although both increase CV risk factors compared to no androgen deprivation therapy. In this spotlight, Matthew R. Smith, MD, PhD, adds to the debate, noting the potential advantages of reversibility of androgen deprivation therapy in high CV risk settings.</p>
<p> </p>
<p><iframe title="Expert Perspectives® in Prostate Cancer Podcast Spotlight 2025" width="500" height="281" src="https://www.youtube.com/embed/97BcqauPuIE?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe></p>
References
Gillessen S, Turco F, Davis ID, et al. Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025;87(2):157-216. doi:10.1016/j.eururo.2024.09.017
Lopes RD, Higano CS, Slovin SF, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144(16):1295-1307. doi:10.1161/CIRCULATIONAHA.121.056810
Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187-2196. doi:10.1056/NEJMoa2004325
